-

09:26:06 AM

MYNZ Stock News

MYNZ - Mainz Biomed B.V.

08/03/22 3:01 AM

Nasdaq : MYNZ

managementlow float

Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz

RHEA-AI

very positive

07/19/22 3:01 AM

Nasdaq : MYNZ

managementlow float

Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

Renowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer Diagnostics Dr. Wang is the GI (Gastrointestinal) Division Chief at Columbia University Vagelos College of Physicians and Surgeons and serves as Co-leader of the Tumor Biology and

RHEA-AI

very positive

07/12/22 3:01 AM

Nasdaq : MYNZ

low float

Mainz Biomed Today to Provide Corporate Update for First Half of 2022

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, will host a

RHEA-AI

neutral

07/05/22 3:01 AM

Nasdaq : MYNZ

low float

Mainz Biomed Provides Corporate Update for First Half of 2022

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to host a

RHEA-AI

very positive

06/28/22 3:01 AM

Nasdaq : MYNZ

low float

Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company

RHEA-AI

neutral

06/14/22 3:01 AM

Nasdaq : MYNZ

managementclinical triallow float

Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission

Jane Edwards, CCRA, RAC brings over 20 years of senior experience developing optimal product and clinical trial strategies in diagnostics and medical devices Will manage the design and logistical operations of Mainz Biomed’s clinical trials in the US and Europe to support FDA submission BERKELEY,

RHEA-AI

very positive

06/01/22 3:01 AM

Nasdaq : MYNZ

low float

Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz

RHEA-AI

neutral

05/19/22 3:01 AM

Nasdaq : MYNZ

partnershiplow float

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or

RHEA-AI

very positive

05/17/22 3:01 AM

Nasdaq : MYNZ

conferenceslow float

Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating

RHEA-AI

neutral

05/09/22 8:01 AM

Nasdaq : MYNZ

conferenceslow float

Mainz Biomed to Host Key Opinion Leader Event at DDW 2022

Mainz Biomed N.V. (NASDAQ:MYNZ)

RHEA-AI

neutral